Research from the STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) demonstrates that GLP-1 agonists produce 1522% body weight loss in people with obesity, significantly outperforming older weight loss medications
Boosting energy during caloric restriction
Unlike tirzepatide, 5-amino-1MQ has a much shorter half-life
Ozempic (semaglutide) is a GLP-1 receptor agonist licensed for type 2 diabetes, administered weekly by subcutaneous injection
M.StranieriC.CominaciniL.MozziniC
The new study, published in Nature Health, covers more than half a decade of posts from nearly 70,000 Reddit users and highlights two main classes of symptoms that warrant further study: reproductive symptoms, including irregular menstrual cycles, and temperature-related complaints, such as chills and hot flashes